ECSP21044734A - FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFBeta - Google Patents

FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFBeta

Info

Publication number
ECSP21044734A
ECSP21044734A ECSENADI202144734A ECDI202144734A ECSP21044734A EC SP21044734 A ECSP21044734 A EC SP21044734A EC SENADI202144734 A ECSENADI202144734 A EC SENADI202144734A EC DI202144734 A ECDI202144734 A EC DI202144734A EC SP21044734 A ECSP21044734 A EC SP21044734A
Authority
EC
Ecuador
Prior art keywords
polymorphic forms
novel polymorphic
tgfbeta inhibitor
relates
tgfbeta
Prior art date
Application number
ECSENADI202144734A
Other languages
English (en)
Inventor
Iain David Roy
Anand Venkataramana Sistla
Andrew Robbins
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP21044734A publication Critical patent/ECSP21044734A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/18—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a formas amorfas y polimórficas cristalinas novedosas de 4-(2-(5-cloro-2-fluorofenil)-5-isopropilpiridin-4-ilamino)-N-(1,3-dihidroxipropan-2-il)nicotinamida y a métodos para su preparación; la invención también se refiere a composiciones farmacéuticas que contienen al menos una forma polimórfica y al uso terapéutico o profiláctico de tales composiciones y formas polimórficas.
ECSENADI202144734A 2018-12-20 2021-06-18 FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFBeta ECSP21044734A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782411P 2018-12-20 2018-12-20
US201962930170P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
ECSP21044734A true ECSP21044734A (es) 2021-07-30

Family

ID=69159846

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202144734A ECSP21044734A (es) 2018-12-20 2021-06-18 FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFBeta

Country Status (22)

Country Link
US (1) US20200199104A1 (es)
EP (1) EP3898591A1 (es)
JP (1) JP2022513925A (es)
KR (1) KR20210104808A (es)
CN (1) CN113272279A (es)
AU (1) AU2019404250B2 (es)
BR (1) BR112021010577A2 (es)
CA (1) CA3123829A1 (es)
CL (1) CL2021001602A1 (es)
CO (1) CO2021007875A2 (es)
CR (1) CR20210334A (es)
EC (1) ECSP21044734A (es)
IL (1) IL284226A (es)
MA (1) MA54526A (es)
MX (1) MX2021007251A (es)
PE (1) PE20211756A1 (es)
PH (1) PH12021551459A1 (es)
PY (1) PY19106776A (es)
SG (1) SG11202105763SA (es)
TW (1) TWI743631B (es)
UY (1) UY38517A (es)
WO (1) WO2020128850A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111244XA (en) 2019-04-12 2021-11-29 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
WO2022130206A1 (en) * 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
CN112843058A (zh) * 2021-01-27 2021-05-28 复旦大学附属华山医院 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用
WO2022229846A1 (en) * 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN120114413B (zh) * 2025-03-17 2025-11-21 珠海市人民医院 一种pH-超声双响应白蛋白纳米药物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania

Also Published As

Publication number Publication date
PE20211756A1 (es) 2021-09-07
AU2019404250B2 (en) 2022-12-22
CO2021007875A2 (es) 2021-07-19
IL284226A (en) 2021-08-31
SG11202105763SA (en) 2021-07-29
KR20210104808A (ko) 2021-08-25
CL2021001602A1 (es) 2022-01-21
BR112021010577A2 (pt) 2021-08-24
CR20210334A (es) 2021-07-14
CN113272279A (zh) 2021-08-17
US20200199104A1 (en) 2020-06-25
EP3898591A1 (en) 2021-10-27
PH12021551459A1 (en) 2022-04-11
TW202039462A (zh) 2020-11-01
WO2020128850A1 (en) 2020-06-25
UY38517A (es) 2020-07-31
AU2019404250A1 (en) 2021-07-01
MA54526A (fr) 2022-03-30
PY19106776A (es) 2021-06-16
CA3123829A1 (en) 2020-06-25
MX2021007251A (es) 2021-07-15
JP2022513925A (ja) 2022-02-09
TWI743631B (zh) 2021-10-21

Similar Documents

Publication Publication Date Title
CL2021001602A1 (es) Formas polimórficas novedosas de un inhibidor de tgfß
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
CL2019000477A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino.
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
MX2017002954A (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2019012967A (es) Cristal de base libre de derivados benzofurano y metodo de preparacion.
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
ZA202103228B (en) Crystal forms of an alk2 inhibitor
EA202090119A1 (ru) Аморфные и кристаллические формы ido-ингибиторов
NI201500139A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
MX2024015245A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas
CO2020011860A2 (es) Compuestos de 4–metildihidropirimidinona y su uso farmacéutico
AR082418A1 (es) Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
BR112022002772A2 (pt) Formas cristalinas de análogos de quinolina e sais dos mesmos, composições e seus métodos para uso
AR103801A1 (es) Formas cristalinas de un compuesto de pirrolopiridina
MX2024002113A (es) Un procedimiento para la preparacion de compuesto de triaminopirimidina e intermediarios del mismo.
MX2022002829A (es) Formulaciones farmaceuticas de inhibidores de indolamina 2,3-dioxigenasa.